menu search

COCP / Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-. Read More
Posted: Apr 12 2022, 11:08
Author Name: Benzinga
Views: 101868

COCP News  

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

By Benzinga
April 12, 2022

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemi more_horizontal

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

By Benzinga
January 27, 2022

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

By Benzinga
January 27, 2022

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

By Benzinga
January 27, 2022

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

By GlobeNewsWire
October 6, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

By GlobeNewsWire
October 6, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

By GlobeNewsWire
October 6, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal


Search within

Pages Search Results: